Updated:
Woodford Patient Capital Trust
Neil Woodford, formerly a star fund manager at Invesco Perpetual, founded Woodford Patient Capital Trust (WPCT) in 2015 as a listed vehicle to invest in...
Woodford Patient Capital Trust
Neil Woodford, formerly a star fund manager at Invesco Perpetual, founded Woodford Patient Capital Trust (WPCT) in 2015 as a listed vehicle to invest in unquoted and early-stage companies. The trust raised £800 million at IPO, a record for a UK investment trust at the time (per Financial Times, 2015). Wealth origin is tied to Woodford's career earnings and reputation from his previous fund management roles; no single-family office wealth backs the trust. The trust invested primarily in healthcare, biotech, and technology startups, often taking significant minority stakes. Portfolio companies included Prothena (a neuroscience biotech), BenevolentAI (an AI drug discovery firm), and Rutherford Health (a cancer care provider). The strategy involved holding positions for five to ten years, but liquidity mismatches emerged when redemptions from Woodford's open-ended Equity Income Fund forced the trust to sell assets at distressed prices. Geographic focus was predominantly the UK, with some exposure to US and European companies. Woodford Patient Capital Trust was a listed entity on the London Stock Exchange, with a small team based in Exeter and an additional office in Boston. The trust had no known philanthropic or operating-company affiliates beyond Neil Woodford's personal foundation. In June 2019, the trust's shares were suspended after the fund manager was unable to meet redemption requests, following a sharp decline in net asset value (per Bloomberg, June 2019). The trust was later wound down, with assets sold and proceeds returned to shareholders by 2022. The trust's key structural differentiator was its 'patient capital' model — a closed-end structure intended to match long-term illiquid investments with long-term capital. In practice, the structure failed when the open-ended sister fund created a liquidity mismatch, and the trust's board was unable to prevent the fire sale. The collapse highlighted governance risks in fund structures reliant on a single manager.
General information
Firm type
Asset Manager
Year founded
2015
AUM
Undisclosed
Location
Region
Europe
Country
United Kingdom
City
Exeter
Corporate office
Exeter, United Kingdom
Additional offices
Boston, United Kingdom
Principals
Neil Woodford
Founder and Fund Manager
Sector focus
Frequently asked questions
What caused the collapse of Woodford Patient Capital Trust?
The trust collapsed due to a liquidity crisis in June 2019. Its open-ended sister fund, the Woodford Equity Income Fund, faced heavy redemption requests and was forced to sell assets, including holdings in unquoted companies held by WPCT. This triggered a suspension of WPCT's shares and a fire sale of its portfolio at depressed prices (per Bloomberg, June 2019).
How was Woodford Patient Capital Trust structured?
WPCT was a closed-end investment trust listed on the London Stock Exchange. It raised £800 million at its 2015 IPO and was designed to invest in illiquid early-stage companies with a five- to ten-year horizon. The closed-end structure was meant to give the manager patient capital, but the trust's liquidity was undermined by its connection to an open-ended fund managed by the same firm (per Financial Times, 2015).
What types of companies did the trust invest in?
The trust focused on early-stage healthcare, biotech, and technology companies. Notable investments included Prothena, BenevolentAI, and Rutherford Health. The portfolio primarily held unquoted or thinly traded equities, making it vulnerable to valuation changes and liquidity shocks (public record).
Who managed Woodford Patient Capital Trust?
The trust was managed by Neil Woodford, a former fund manager at Invesco Perpetual. Woodford was the single named principal and the sole decision-maker for the portfolio. No other senior investment professionals were publicly disclosed (public record).
What happened to investors after the trust was wound down?
After the suspension in 2019, the trust's assets were sold off over several years, with proceeds returned to shareholders. The final distribution was completed in 2022. Investors recovered only a fraction of their original capital, with significant losses (per Financial Times, 2022).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: